1
|
Verma V, Kumar P, Gupta S, Yadav S, Dhanda RS, Yadav M. NLRP3‐mediated dysfunction of mitochondria leads to cell death in CFT073‐stimulated macrophages. Scand J Immunol 2021. [DOI: 10.1111/sji.13104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Vivek Verma
- Dr. B. R. Ambedkar Center for Biomedical Research University of Delhi Delhi India
| | - Parveen Kumar
- Department of Urology University of Alabama at Birmingham Birmingham Alabama USA
| | - Surbhi Gupta
- Dr. B. R. Ambedkar Center for Biomedical Research University of Delhi Delhi India
| | - Sonal Yadav
- Dr. B. R. Ambedkar Center for Biomedical Research University of Delhi Delhi India
| | | | - Manisha Yadav
- Dr. B. R. Ambedkar Center for Biomedical Research University of Delhi Delhi India
| |
Collapse
|
2
|
Siegel PM, Hentschel D, Bojti I, Wengenmayer T, Helbing T, Moser M, Duerschmied D, Trummer G, Bode C, Diehl P. Annexin V positive microvesicles are elevated and correlate with flow rate in patients receiving veno-arterial extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg 2021; 31:884-891. [PMID: 33164057 DOI: 10.1093/icvts/ivaa198] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 07/21/2020] [Accepted: 08/16/2020] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is used in critically ill patients requiring haemodynamic support. Microvesicles (MV) are released by activated blood cells acting as mediators of intercellular communication. We aimed to determine MV count and composition over time in patients with VA-ECMO and explore what drives MV formation. METHODS VA-ECMO patients and healthy controls were recruited prospectively, and blood was taken at different time points (day 0, 1, 3 after ECMO placement and after explantation) for MV analysis. RESULTS Annexin V positive MV were increased in patients (n = 14, mean age = 61.4 ± 9.0 years, 11 males, 3 females) compared to healthy controls (n = 6, Annexin V positive MV count per millilitre day 1 versus healthy controls: 2.3 × 106 vs 1.3 × 105, P < 0.001). Furthermore, patients had higher proportions of endothelial and leukocyte MV [leukocyte MV day 1 versus healthy controls (%): 32.8 vs 17.5, P = 0.001; endothelial MV day 1 versus healthy controls (%): 10.5 vs 5.5, P = 0.01]. Annexin V positive and leucocyte MV correlated with the flow rate (r = 0.46, P = 0.01). CONCLUSIONS Patients on VA-ECMO have increased levels of circulating MV and a changed MV composition. Our data support the hypothesis that MV release may be driven by higher flow rate and cellular activation in the extracorporeal circuit leading to poor outcomes in these patients. CLINICAL TRIAL REGISTRATION NUMBER German Clinical Trials Register-ID: DRKS00011106.
Collapse
Affiliation(s)
- Patrick M Siegel
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Dominik Hentschel
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - István Bojti
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Tobias Wengenmayer
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Thomas Helbing
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Martin Moser
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Daniel Duerschmied
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Georg Trummer
- Department of Cardiovascular Surgery, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Christoph Bode
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| | - Philipp Diehl
- Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, Freiburg, Germany
| |
Collapse
|
3
|
Jayachandran M, Garovic VD, Mielke MM, Bailey KR, Lahr BD, Miller VM. Characterization of intravascular cellular activation in relationship to subclinical atherosclerosis in postmenopausal women. PLoS One 2017; 12:e0183159. [PMID: 28910282 PMCID: PMC5598935 DOI: 10.1371/journal.pone.0183159] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 07/31/2017] [Indexed: 02/02/2023] Open
Abstract
Objective Mechanisms and interactions among intravascular cells contributing to development of subclinical atherosclerosis are poorly understood. In women, both menopausal status and pregnancy history influence progression of atherosclerosis. This study examined activation and interactions among blood elements with subclinical atherosclerosis in menopausal women with known pregnancy histories. Methods Carotid intima-media thickness (CIMT), as a marker of subclinical atherosclerosis, was measured using B-mode ultrasound in age- and parity-matched women [40 with and 40 without a history of preeclampsia] 35 years after the index pregnancy. Interactions among intravascular cells (38 parameters) were measured by flow cytometry in venous blood. Data analysis was by principal component which retained 7 independent dimensions accounting for 63% of the variability among 38 parameters. Results CIMT was significantly greater in women with a history of preeclampsia (P = 0.004). Platelet aggregation and platelet interactions with granulocytes and monocytes positively associated with CIMT in postmenopausal women independent of their pregnancy history (ρ = 0.258, P< 0.05). However, the association of the number of platelets, platelet activation and monocyte-platelet interactions with CIMT differed significantly depending upon pregnancy history (test for interaction, P<0.001). Conclusion Interactions among actived intravascular cells and their association with subclinical atherosclerosis differ in women depending upon their pregnancy histories.
Collapse
Affiliation(s)
- Muthuvel Jayachandran
- Departments of Surgery, Mayo Clinic, Rochester, Minnesota, United States of America
- Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Vesna D. Garovic
- General Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Michelle M. Mielke
- Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, United States of America
- Neurology, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Kent R. Bailey
- Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, United States of America
- Health Science Research, Division of Biostatistics, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Brian D. Lahr
- Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, United States of America
- Health Science Research, Division of Biostatistics, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Virginia M. Miller
- Departments of Surgery, Mayo Clinic, Rochester, Minnesota, United States of America
- Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, United States of America
- * E-mail:
| |
Collapse
|
4
|
Miller VM, Lahr BD, Bailey KR, Heit JA, Harman SM, Jayachandran M. Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles. Platelets 2015; 27:32-42. [PMID: 25856160 PMCID: PMC4732432 DOI: 10.3109/09537104.2015.1023273] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Activated platelets serve as a catalyst for thrombin generation and a source of vasoactive and mitogenic factors affecting vascular remodeling. Oral menopausal hormone treatments (MHT) may carry greater thrombotic risk than transdermal products. This study compared effects of oral and transdermal MHT on platelet characteristics, platelet proteins, and platelet-derived microvesicles (MV) in recently menopausal women. Platelets and MV were prepared from blood of a subset of women (n = 117) enrolled in the Kronos Early Estrogen Prevention Study prior to and after 48 months of treatment with either oral conjugated equine estrogen (0.45 mg/day), transdermal 17β-estradiol (50 µg/day), each with intermittent progesterone (200 mg/day for 12 days a month), or placebo pills and patch. Platelet count and expression of platelet P-selectin and fibrinogen receptors were similar across groups. An aggregate measure of 4-year change in vasoactive and mitogenic factors in platelet lysate, by principle component analysis, indicated significantly lower values in both MHT groups compared to placebo. Increases in numbers of tissue factor positive and platelet-derived MV were significantly greater in the transdermal compared to placebo group. MHT was associated with significantly reduced platelet content of vasoactive and mitogenic factors representing a potential mechanism by which MHT may affect vascular remodeling. Various hormonal compositions and doses of MHT could differentially regulate nuclear transcription in bone marrow megakaryocytes and non-genomic pathways in circulating platelets thus determining numbers and characteristics of circulating MV. Thrombotic risk associated with oral MHT most likely involves liver-derived inflammatory/coagulation proteins rather than circulating platelets per se.
Collapse
Affiliation(s)
- Virginia M Miller
- a Department of Surgery , College of Medicine, Mayo Clinic , Rochester , MN , USA .,b Department of Physiology & Biomedical Engineering , Mayo Clinic , Rochester , MN , USA
| | - Brian D Lahr
- c Division of Biomedical Statistics and Informatics , Mayo Clinic , Rochester , MN , USA
| | - Kent R Bailey
- c Division of Biomedical Statistics and Informatics , Mayo Clinic , Rochester , MN , USA .,d Division of Epidemiology , Mayo Clinic , Rochester , MN , USA
| | - John A Heit
- e Division of Cardiovascular Diseases , Internal Medicine, Mayo Clinic , Rochester , MN , USA , and
| | - S Mitchell Harman
- f Kronos Longevity Research Institute and Phoenix VA Health Care System , Phoenix , AZ , USA
| | - Muthuvel Jayachandran
- b Department of Physiology & Biomedical Engineering , Mayo Clinic , Rochester , MN , USA
| |
Collapse
|
5
|
McManus DD, Beaulieu LM, Mick E, Tanriverdi K, Larson MG, Keaney JF, Benjamin EJ, Freedman JE. Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk. Arterioscler Thromb Vasc Biol 2013; 33:2666-73. [PMID: 23968978 DOI: 10.1161/atvbaha.112.301112] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Cardiovascular disease is a complex disorder influenced by interactions of genetic variants with environmental factors. However, there is no information from large community-based studies examining the relationship of circulating cell-specific RNA to inflammatory proteins. In light of the associations among inflammatory biomarkers, obesity, platelet function, and cardiovascular disease, we sought to examine the relationships of C-reactive protein (CRP) and interleukin-6 (IL-6) to the expression of key inflammatory transcripts in platelets. APPROACH AND RESULTS We quantified circulating levels of CRP and IL-6 in 1625 participants of the Framingham Heart Study (FHS) Offspring cohort examination 8 (mean age, 66.6 ± 6.6 years; 46% men). We measured the expression of 15 relevant genes by high-throughput quantitative reverse transcriptase polymerase chain reaction from platelet-derived RNA and used multivariable regression to relate serum concentrations of CRP and IL-6 with gene expression. Levels of CRP and IL-6 were associated with 10 of the 15 platelet-derived inflammatory transcripts, ALOX5, CRP, IFIT1, IL6, PTGER2, S100A9, SELENBP1, TLR2, TLR4, and TNFRSF1B (P<0.001). Associations between platelet mRNA expression with CRP and IL-6 persisted after multivariable adjustment for potentially confounding factors. Six genes positively associated with CRP or IL-6 in the FHS sample were also upregulated in megakaryocytes in response to CRP or IL-6 exposure. CONCLUSIONS Our data highlight the strong connection between the circulating inflammatory biomarkers CRP and IL-6 and platelet gene expression, adjusting for cardiovascular disease risk factors. Our results also suggest that body weight may directly influence these associations.
Collapse
Affiliation(s)
- David D McManus
- From the National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA (D.D.M., K.T., M.G.L., J.E.F.); Cardiology Division, Department of Medicine (D.D.M, L.M.B., K.T., J.F.K., J.E.F.) and Epidemiology Division, Department of Quantitative Health Sciences (D.D.M, E.M.), University of Massachusetts Medical School, Worcester, MA; Section of Cardiovascular Medicine, Department of Medicine (E.J.B.) and Department of Mathematics and Statistics (M.G.L.), Boston University, Boston, MA; Preventive Medicine Section, Department of Medicine, Boston University School of Medicine, Boston, MA (E.J.B.); and Department of Epidemiology (E.J.B.) and Department of Biostatistics (M.G.L.), Boston University School of Public Health, Boston, MA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Albitar M, Bacharach A. Company Profile: NeoGenomics Laboratories, Inc. Per Med 2012; 9:795-799. [PMID: 29776233 DOI: 10.2217/pme.12.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
NeoGenomics Laboratories, Inc. is a publicly traded high-complexity national clinical laboratory company that specializes in cancer diagnostic testing, focused on molecular and genomic approaches. NeoGenomics has been associated with innovation in providing world-class pathology and cancer genetic diagnostic services for pathologists, oncologists, urologists and gastroenterologists, as well as hospitals throughout the USA. The company mission also includes the integration of technical advances in molecular methodologies including computer-aided pattern-recognition mathematical algorithms in order to integrate data from multiple analytes and thereby develop precise (personalized) predictive tools for the diagnosis of disease, prognosis and response to therapy. The company has a unique business model in that it is committed to partnering with routine diagnostic laboratories, thereby providing them with the option of technical-component-only testing for esoteric biomarkers and allowing local control of the professional component, in the interpretation and the review of raw data. The company, through innovative research and development, is dedicated to the cost-effective delivery of leading-edge, high-quality patient care through the application of precise and personalized laboratory medicine.
Collapse
Affiliation(s)
- Maher Albitar
- NeoGenomics Laboratories, 5 Jenner Street, Irvine, CA 92618, USA.
| | - Alfred Bacharach
- NeoGenomics Laboratories, 5 Jenner Street, Irvine, CA 92618, USA
| |
Collapse
|